Cargando…

Potential of antithrombin III as a biomarker of antidepressive effect in major depressive disorder

INTRODUCTION: Previous study has identified increased antithrombin III (ATIII) in patients with major depressive disorder (MDD), supporting ATIII as a potential biomarker for depression diagnosis. OBJECTIVES: This study aimed to reveal the alteration of ATIII after occipital repetitive transcranial...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, R., Shi, Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2021
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9470394/ http://dx.doi.org/10.1192/j.eurpsy.2021.310

Ejemplares similares

Potential of Antithrombin III as a Biomarker of Antidepressive Effect in Major Depressive Disorder
por: Song, Ruize, et al.
Publicado: (2021)

Inhibition of neutrophil migration by the serpin antithrombin III
por: Dunzendorfer, S, et al.
Publicado: (2000)

The effect of antidepressant treatment on white matter integrity in Major Depression
por: Tourjman, S., et al.
Publicado: (2022)

Specific deactivation of monocyte and lymphocyte migration by antithrombin III
por: Reinisch, C, et al.
Publicado: (2001)

Depression patient-derived cortical neurons reveal potential biomarkers for antidepressant response
por: Avior, Y., et al.
Publicado: (2021)

Longitudinal effects of antidepressant treatment on resting state functional connectivity in adolescents with major depressive disorder
por: Lee, K.H., et al.
Publicado: (2022)

Effect of antithrombin III on inflammatory immune response in patients with severe sepsis
por: Inthorn, D, et al.
Publicado: (1998)

PS129. Low TNFAIP3 was normalized with antidepressant in patients with major depressive disorder
por: Hung, Yi-Yung
Publicado: (2016)

PS76. Effect of antidepressant therapy on white matter in patients with first-episode major depressive disorder
por: Lee, Chun-Te, et al.
Publicado: (2016)

Vasopressin surrogate marker copeptin as a potential novel endocrine biomarker for antidepressant treatment response in major depression: A pilot study
por: Agorastos, A., et al.
Publicado: (2021)

Potential objective diagnostic biomarker platform of serum proteins for major depressive disorder:a preliminary exploration
por: Chen, S., et al.
Publicado: (2021)

Effects of Antidepressant Treatment on Peripheral Biomarkers in Patients with Major Depressive Disorder (MDD)
por: Mosiołek, Anna, et al.
Publicado: (2021)

PS97. Serum Cytokine Levels in Major Depressive Disorder and Its Role in Antidepressant Response
por: Myung, Woojae, et al.
Publicado: (2016)

PS188. Predict value of functional topological features for early response to antidepressant treatment in major depressive disorder
por: Hou, Zhenghua, et al.
Publicado: (2016)

Inhibition of endotoxin-induced leukocyte/endothelial cell interaction by antithrombin III
por: Hoffmann, JN, et al.
Publicado: (1999)

Less basal thyrotropin levels predict antidepressant response in patients with major depression
por: Navinés, R., et al.
Publicado: (2022)

Use of antithrombin III in cancer patients with sepsis complicated with disseminated intravascular coagulopathy
por: Polansky, M, et al.
Publicado: (1998)

Effectiveness of antidepressants in bipolar depression
por: Potanin, S., et al.
Publicado: (2021)

Pharmacogenetics to Personalize Dosing of Tricyclic Antidepressants in Major Depressive Disorder: A Randomized Clinical Trial (PITA study)
por: Ter Hark, S., et al.
Publicado: (2023)

Should antidepressants be used for major depressive disorder?
por: Jakobsen, Janus Christian, et al.
Publicado: (2020)

Antithrombin III (AT III) prevents increased permeability and leukocyte adhesion in response to endotoxin (LPS) in the microcirculation of rat mesentery
por: Leithäuser, B, et al.
Publicado: (1999)

Inhibition of HCV by the serpin antithrombin III
por: Asmal, Mohammed, et al.
Publicado: (2012)

Proper diagnosis of antithrombin III deficiency
por: Özdemir, Zehra Narlı, et al.
Publicado: (2017)

Telomere length from peripheral blood DNA in major depressive disorder: a case/control comparison and association with antidepressant treatment response
por: Kalinovic, R., et al.
Publicado: (2023)

PS46. Distinct and shared morphometric biomarkers of depressed individuals with bipolar disorder and major depressive disorder
por: Matsuo, Koji, et al.
Publicado: (2016)

Therapeutic Antidepressant Potential of NONHSAG045500 in Regulating Serotonin Transporter in Major Depressive Disorder
por: Liu, Song, et al.
Publicado: (2018)

Effect of Immobilized Antithrombin III on the Thromboresistance of Polycarbonate Urethane
por: Lukas, Karin, et al.
Publicado: (2017)

PS78. Naturalistic, retrospective comparison between antidepressant therapy and atypical antipsychotic augmentation therapy for patients with major depressive disorder
por: Cho, Se Hoon, et al.
Publicado: (2016)

Distinct antithrombin III preparations deactivate IL-8-induced neutrophil chemotaxis with different potency
por: Kaneider, N, et al.
Publicado: (2001)

Antibodies to beta(2)-glycoprotein I, prothrombin and antithrombin III as markers of the antiphospholipid syndrome severity
por: Zabek, J, et al.
Publicado: (2001)

PS180. Relationship between frontal lobe function and antidepressant treatment in bipolar disorder and major depressive disorder: a near-infrared spectroscopy study
por: Tomioka, Hiroi, et al.
Publicado: (2016)

PS92. Serum BDNF and GDNF levels before and after the 12-week antidepressant treatments among outpatients with major depressive disorder
por: Lee, Bun-Hee, et al.
Publicado: (2016)

Effects of Antithrombin III on body cavity effusions, fluid balance, colloid osmotic pressure and hemodynamics in porcine septic shock
por: Cobas Meyer, M, et al.
Publicado: (2000)

Deficiency Of Antithrombin III (AT III) - Case Report and Review of the Literature
por: GĂMAN, AMELIA MARIA, et al.
Publicado: (2014)

G-protein- and phosphodiesterase-dependent regulation of neutrophil migration by antithrombin III involving CXC-receptor 1
por: Dunzendorfer, S, et al.
Publicado: (2000)

Genetic Landscape of Major Depressive Disorder: Assessment of Potential Diagnostic and Antidepressant Response Markers
por: Singh, Priyanka, et al.
Publicado: (2023)

Neutrophil-to-lymphocyte ratio, Factor VIII and Antithrombin III: inflammatory-clotting biomarkers in glioma
por: Koudriavtseva, Tatiana, et al.
Publicado: (2021)

Brain aging in major depressive disorder
por: Han, L., et al.
Publicado: (2021)

PS82. Does Serum Amyloid ß-Protein predict the Response to Antidepressant treatment in Major Depression?
por: Inoue, Megumi, et al.
Publicado: (2016)

ARPNet: Antidepressant Response Prediction Network for Major Depressive Disorder
por: Chang, Buru, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ig1vkajdhisuriei7bed6so6ug